rabbit polyclonal anti human cb2r  (Alomone Labs)

Journal: CNS Neuroscience & Therapeutics

Article Title: Update on the controversial identity of cells expressing cnr2 gene in the nervous system

doi: 10.1111/cns.13977

Figure Lengend Snippet: List of anti‐CB2R antibodies used for the detection of CB2R protein in the central nervous system

Article Snippet: E , #ACR‐003 , Alomone , No , aa 11–24 of human CB2R , Rabbit , Poly , Human.

Techniques:

Journal: Nanomaterials

Article Title: ZnO Nanoparticles Induce Dyslipidemia and Atherosclerotic Lesions Leading to Changes in Vascular Contractility and Cannabinoid Receptors Expression as Well as Increased Blood Pressure

doi: 10.3390/nano11092319

Figure Lengend Snippet: Effect of ZnONPs on aorta contractility. ( a ) Effect of ACPA (CB 1 receptor agonist) on contraction in aortic rings in different experimental groups. ( b ) Effect of HU308 (CB 2 receptor agonist) on contraction in aortic rings in different experimental groups. Blue bars correspond to the control non-treated group, green bars correspond to the ZnONPs treated-groups at different times; ( a ) there is a significant difference compared to the phenylephrine group with p < 0.05; ( b ) there is a significant difference compared to the control group with p < 0.05.

Article Snippet: Next, aorta sections were blocked (Animal-free blocker and diluent, Vector laboratories Inc., Burlingame, CA, USA) and incubated with rabbit polyclonal Anti-CB 1 (1:100, Alomone, Labs, Jerusalem, Israel) or rabbit polyclonal Anti-CB 2 (1:100, Alomone, Labs, Jerusalem, Israel) primary antibody and co-labeled with mouse monoclonal Anti-alpha smooth muscle Actin antibody (1:200, Abcam, Cambrige, UK) overnight.

Techniques:

Journal: Nanomaterials

Article Title: ZnO Nanoparticles Induce Dyslipidemia and Atherosclerotic Lesions Leading to Changes in Vascular Contractility and Cannabinoid Receptors Expression as Well as Increased Blood Pressure

doi: 10.3390/nano11092319

Figure Lengend Snippet: Effect of ZnONPs on the CB 1 and CB 2 receptors expression in the aorta wall. ( a ) CB 1 expression, ( b ) CB 2 expression. Blue bars correspond to the control non-treated group, green bars correspond to the ZnONPs treated-groups at different times; ( a ) there is a significant difference compared to the control group with p < 0.05.

Article Snippet: Next, aorta sections were blocked (Animal-free blocker and diluent, Vector laboratories Inc., Burlingame, CA, USA) and incubated with rabbit polyclonal Anti-CB 1 (1:100, Alomone, Labs, Jerusalem, Israel) or rabbit polyclonal Anti-CB 2 (1:100, Alomone, Labs, Jerusalem, Israel) primary antibody and co-labeled with mouse monoclonal Anti-alpha smooth muscle Actin antibody (1:200, Abcam, Cambrige, UK) overnight.

Techniques: Expressing

Journal: Nanomaterials

Article Title: ZnO Nanoparticles Induce Dyslipidemia and Atherosclerotic Lesions Leading to Changes in Vascular Contractility and Cannabinoid Receptors Expression as Well as Increased Blood Pressure

doi: 10.3390/nano11092319

Figure Lengend Snippet: Representative images showed ZnONPs effect on CB 1 and CB 2 receptors expression in aorta wall. Transmitted light images (grey). Scale bar corresponds to 50 μm. Smooth muscle α-actin was detected with a specific antibody labeled with Alexa Fluor 568 (red). CB 1 and CB 2 located on the aorta ring were detected by specific antibodies and labeled with FITC (green). Image overlap indicates a high degree of colocalization of CB 1 or CB 2, and smooth muscle α-actin (yellow). Nuclei were counterstained with DAPI dye (blue).

Article Snippet: Next, aorta sections were blocked (Animal-free blocker and diluent, Vector laboratories Inc., Burlingame, CA, USA) and incubated with rabbit polyclonal Anti-CB 1 (1:100, Alomone, Labs, Jerusalem, Israel) or rabbit polyclonal Anti-CB 2 (1:100, Alomone, Labs, Jerusalem, Israel) primary antibody and co-labeled with mouse monoclonal Anti-alpha smooth muscle Actin antibody (1:200, Abcam, Cambrige, UK) overnight.

Techniques: Expressing, Labeling